Association of MammaPrint index and 3-year outcome of patients with HR+HER2-early-stage breast cancer treated with chemotherapy with or without anthracycline

被引：0
|
作者：
O'Shaughnessy, Joyce
Graham, Cathy Lynne
Whitworth, Pat
Beitsch, Peter D.
Osborne, Cynthia R. C.
Rahman, Rakhshanda Layeequr
Brown, Eric Allen
Gold, Linsey P.
Johnson, Nathalie Mcdowell
Brufsky, Adam
Ramaswamy, Harshini
Stivers, Nicole
Menicucci, Andrea
Audeh, M. William
机构：
[1] Baylor Univ, Med Ctr, Texas Oncol, US Oncol Network, Dallas, TX USA
[2] Emory Univ, Atlanta, GA USA
[3] Nashville Breast Ctr, Nashville, TN USA
[4] Dallas Surg Grp, Dallas, TX USA
[5] Texas Tech Univ, Hlth Sci Ctr, Sch Med, Lubbock, TX USA
[6] Comprehens Breast Care, Troy, MI USA
[7] Legacy Hlth Syst, Portland, OR USA
[8] Univ Pittsburgh, Pittsburgh, PA USA
[9] Agendia Inc, Med Affairs, Irvine, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
511
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Trastuzumab plus chemotherapy improves survival in early-stage HER2-positive breast cancer patients
    不详
    ONCOLOGY-NEW YORK, 2005, 19 (07): : 851 - +
  • [42] Effect of different chemotherapy schemes on early-stage breast cancer patients with Low HER-2 expression
    Xu, Yurui
    Chao, Lin
    Wang, Jianyu
    Sun, Yonghong
    Li, Chen
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2023, 39 (05) : 1355 - 1360
  • [43] Effect of PREDICT on chemotherapy/trastuzumab recommendations in HER2-positive patients with early-stage breast cancer
    Down, Sue K.
    Lucas, Olivia
    Benson, John R.
    Wishart, Gordon C.
    ONCOLOGY LETTERS, 2014, 8 (06) : 2757 - 2761
  • [44] Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients
    Sawaki, Masataka
    Taira, Naruto
    Uemura, Yukari
    Saito, Tsuyoshi
    Baba, Shinichi
    Kobayashi, Kokoro
    Kawashima, Hiroaki
    Tsuneizumi, Michiko
    Sagawa, Noriko
    Bando, Hiroko
    Takahashi, Masato
    Yamaguchi, Miki
    Takashima, Tsutomu
    Nakayama, Takahiro
    Kashiwaba, Masahiro
    Mizuno, Toshiro
    Yamamoto, Yutaka
    Iwata, Hiroji
    Kawahara, Takuya
    Ohashi, Yasuo
    Mukai, Hirofumi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (32) : 3743 - +
  • [45] Adjuvant chemotherapy for HER2-positive early breast cancer patients without perioperative radiotherapy in trastuzumab era
    Nozawa, Kazuki
    Sugiyama, Keiji
    Shiraishi, Kazuhiro
    Funahashi, Yoriko
    Kogure, Yoshihito
    Kawasaki, Tomonori
    Kato, Aya
    Kitagawa, Chiyoe
    Hayashi, Takako
    Morita, Takako
    Ichihara, Shu
    Saka, Hideo
    Sato, Yasuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+breast cancer: a plain language summary of the PHERGain study
    Perez-Garcia, Jose Manuel
    Gebhart, Geraldine
    Borrego, Manuel Ruiz
    Schmid, Peter
    Marme, Frederik
    Prat, Aleix
    Dalenc, Florence
    Kerrou, Khaldoun
    Colleoni, Marco
    Braga, Sofia
    Malfettone, Andrea
    Sampayo-Cordero, Miguel
    Cortes, Javier
    Llombart-Cussac, Antonio
    FUTURE ONCOLOGY, 2022, 18 (33) : 3677 - 3688
  • [47] Immune subtyping identifies a subset of HR+HER2-early-stage breast cancer patients with a very high likelihood of response to neoadjuvant immunotherapy (IO): Results from 5 IO arms of the I-SPY2 TRIAL
    Wolf, Denise M.
    Yau, Christina
    Pusztai, Lajos
    Nanda, Rita
    Chien, Jo
    Stringer-Reasor, Erica
    Shatsky, Rebecca
    Isaacs, Claudine
    Liu, MInetta
    Han, Hyo
    Soliman, Hatem
    Campbell, Michael
    Glas, Annuska
    Barcaru, Andrei
    Mittempergher, Lorenza
    Kuilman, Midas
    Swigart, Lamorna Brown
    Hirst, Gillian
    Yu, Hongmei
    Beineke, Philip
    Basu, Amrita
    Yee, Douglas
    Symmans, W. Fraser
    DeMichele, Angela
    Perlmutter, Jane
    Delson, Amy
    Huppert, Laura
    Rugo, Hope
    Clark, Amy
    Hylton, Nola
    Pohlmann, Paula
    Esserman, Laura
    van 't Veer, Laura
    CANCER RESEARCH, 2024, 84 (06)
  • [48] Celtil score and long-term survival outcome in early stage HER2-positive (HER2+) breast cancer treated with anti-HER2-based chemotherapy: A correlative analysis of neoALTTO trial
    Chic, Nuria
    Luen, Stephen
    Nuciforo, Paolo
    Salgado, Roberto
    Fumagalli, Debora
    Hilbers, Florentine
    Wang, Yingbo
    de Azambuja, Evandro
    Lang, Itsvan
    Di Cosimo, Serena
    Saura, Cristina
    Huober, Jens
    Prat, Aleix
    Loi, Sherene
    CANCER RESEARCH, 2021, 81 (04)
  • [49] Relationship of HIF-1α and tumor infiltrating lymphocytes in patients with HER2-negative early-stage breast cancer treated with neoadjuvant chemotherapy
    Oza, Harsh
    Grabinski, Victoria
    Ibanez, Hector
    Godet, Ines
    Gilkes, Daniele
    Cimino-Mathews, Ashley
    Gabrielson, Edward
    Shah, Mirat
    Zhi, W. Iris
    Pipa, Zoe
    Lehman, Jennifer
    Ke, Suqi
    Tsai, Hua-Ling
    Stearns, Vered
    Santa-Maria, Cesar Augusto
    CANCER RESEARCH, 2023, 83 (05)
  • [50] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy: Sequential analysis
    Seo, Y. -J.
    Yu, J. -H.
    Kim, S. -W.
    Lee, J. -E.
    Nam, S. -J.
    Cho, S. -Y.
    Cho, E. -Y.
    VIRCHOWS ARCHIV, 2017, 471 : S61 - S61
12345